<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715468</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080ACA07</org_study_id>
    <nct_id>NCT00715468</nct_id>
  </id_info>
  <brief_title>Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*</brief_title>
  <official_title>Prospective, 6 Month, Open Label, Conversion Study From MMF to MYFORTIC* Evaluating the Severity of GI Symptoms and MPA Metabolite as a Surrogate Marker of MYFORTIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with MMF often results in adverse GI events, which can lead to dose reductions of&#xD;
      MMF and decreased graft function. Enteric-coated mycophenolate sodium (MYFORTIC*) was&#xD;
      developed as an alternative formulation of MPA to improve upper GI tract side effects. An&#xD;
      improvement in the severity of GI side effects could result in an increased tolerance to MPA&#xD;
      and an improvement in patient quality of life. This study will use the GSRS to evaluate&#xD;
      improvement in gastrointestinal symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the change in the total gastrointestinal symptom rating scale (GSRS)&#xD;
      score at baseline versus month 1,at baseline versus month 3 and at baseline versus month 6&#xD;
      after conversion from MMF to PRMYFORTIC* .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the change in the total gastrointestinal symptom rating scale(GSRS) score at baseline vs 1 month, va 3 month and vs 6 month</measure>
    <time_frame>1 month- 3 month-6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the change in the diarrhea GSRS subscale on a per patient basis</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events and serious events at months 3 an d6 will be evaluated</measure>
    <time_frame>month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function and incidence of acute rejection</measure>
    <time_frame>1-3-6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">59</enrollment>
  <condition>Late Complication From Kidney Transplant</condition>
  <eligibility>
    <study_pop>
      <textblock>
        renal transplant patients who have received a transplant at least 3 months and experiencing&#xD;
        Gastrointestinal symptoms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received a kidney transplant at least six months&#xD;
&#xD;
          -  stable graft function (no increased creatinine &gt; 20% in the previous 4 weeks)&#xD;
&#xD;
          -  Receiving immunosuppressive regimen with stable dose of MMF for at least 4 weeks&#xD;
&#xD;
          -  Immunosuppressive regimen with a dose of MMF (dose≤ 2.0 g/day) at least 4 weeks OR C0&#xD;
             MMF &lt; 1.4 µg/ml at visit 1 OR patients receiving MMF who have GI side effects&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  Women of childbearing age must have a negative pregnancy test and use a medically&#xD;
             acceptable method of contraception throughout the treatment period;&#xD;
&#xD;
          -  Over 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GI symptoms assumed or known not to be caused by MPA therapy;&#xD;
&#xD;
          -  Acute rejection episode ≤ 4 weeks prior to study enrollment;&#xD;
&#xD;
          -  Liver disease interfering with enterohepatic recirculation, such as active hepatitis&#xD;
             B, active hepatitis C, autoimmune hepatitis and liver cirrhosis;&#xD;
&#xD;
          -  Female patients who are pregnant, lactating or of child bearing potential and not&#xD;
             practicing an approved method of birth control;&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection;&#xD;
&#xD;
          -  Presence of psychiatric illness that in the view of the investigator would interfere&#xD;
             with study requirements;&#xD;
&#xD;
          -  Known sensitivity to the study drug;&#xD;
&#xD;
          -  Receiving any investigational drug or have received any investigational drug within 30&#xD;
             days prior to study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzon Collette, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Maisonneuve-Rosemont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Suzon Collette</investigator_full_name>
    <investigator_title>Transplantation Nephrologist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

